Table 1.

Inhibitors of MAP4K4 used in different disease studies.

Name	Target	Effects in Disease/Syndrome	Ref
GNE-220	MAP4K4 MAP4K5 (KHS1), MAP4K6 (MINK1), DMPK	Regulation of protrusion formation in human umbilical vein endothelial cells (HUVECs). Suppression of pathological angiogenesis in mice.	(20)
GNE-495	MAP4K4	Inhibition of migration and invasion in neuron protection medulloblastoma. Suppression of retinal angiogenesis.	(6) (20) (49) (51)
PF-06260933	MAP4K4	Reduction in glucose levels, amelioration of plaque development and/or plaque reduction in vivo. Reduction of blood-brain barrier damage in mice, improved neurological recovery.	(23)
4-Hydroxy-2-pyridone	MAP4K4	Enhancement of neurite outgrowth.	(52)
6-(2-fluoropyridin-4-yl)pyrido[3,2-d]pyrimidin-4-amine, Compound 29	MAP4K4	Improved survival of motor neurons. Repression of stress-induced retrograde JNK signaling and protection from neurodegeneration. Pharmacodynamic effects in a human tumor xenograft model.	(47–49)
Kenpaullone	CDK1/cyclin B, GSK-3β, MAP4K4, KLF4, CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25	Inhibition of tumor cell growth. Maintenance of pancreatic β cell survival. Improved cardiomyocyte survival.	(53, 54)
Prostetin/12k	MAP4K4	Protection of motor neurons from ER stress-induced apoptosis in amyotrophic lateral sclerosis (ALS).	(46)
Bosutinib (Bosulif)	BCR-ABL, MAP4K4	Protection against inflammation-induced endothelial barrier disruption. Prevention of vascular leakage and attenuation of murine alveolar protein leakage and pulmonary edema.	(24)
DMX-5804	MAP4K4 MAP4K6 (MINK1), MAP4K7 (TNIK)	Prevention of oxidative-stress in cardiac myocyte cell death. Reduction of ischemia-reperfusion injury in mice.	(54)